Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma

J Allergy Clin Immunol Pract. 2019 Sep-Oct;7(7):2447-2449.e2. doi: 10.1016/j.jaip.2019.03.023. Epub 2019 Mar 27.

Authors

Claus Bachert¹, Peter W Hellings², Joaquim Mullol³, Robert M Naclerio⁴, Jingdong Chao⁵, Nikhil Amin⁵, Annette Grabher⁶, Brian N Swanson⁶, Jennifer D Hamilton⁶, Sophie Guillonneau⁷, Christine Taniou⁸, Donghui Zhang⁶, Gianluca Pirozzi⁶, Neil M H Graham⁵, Heribert Staudinger⁶, Leda P Mannent⁷, Asif Khan⁷

Affiliations

¹ Upper Airway Research Laboratory, Department of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium; CLINTEC, Karolinska Institute, Stockholm, Sweden. Electronic address: Claus.Bachert@UGent.be.
² Laboratory of Experimental Immunology, Department of Otorhinolaryngology-Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium.
³ IDIBAPS, Hospital Clínic Barcelona, University of Barcelona, CIBERES, Barcelona, Catalonia, Spain.
⁴ Johns Hopkins Hospital, Baltimore, Md.
⁵ Regeneron Pharmaceuticals, Inc., Tarrytown, NY.
⁶ Sanofi, Bridgewater, NJ.
⁷ Sanofi, Chilly-Mazarin, France.
⁸ Altran Technologies, Vélizy-Villacoublay, France.

PMID: 30928658
DOI: 10.1016/j.jaip.2019.03.023

No abstract available

Publication types

Letter
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Anti-Allergic Agents / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Asthma
Biomarkers / metabolism
Chronic Disease
Comorbidity
Double-Blind Method
Female
Humans
Inflammation Mediators / metabolism
Male
Middle Aged
Nasal Polyps / diagnosis*
Nasal Polyps / epidemiology
Patient Reported Outcome Measures
Placebos
Rhinitis / drug therapy*
Rhinitis / epidemiology
Sinusitis / drug therapy*
Sinusitis / epidemiology

Substances

Anti-Allergic Agents
Antibodies, Monoclonal, Humanized
Biomarkers
Inflammation Mediators
Placebos
dupilumab